NCAPG: A Protein Targeted for Cancer Treatment (G64151)

Target Name: NCAPG

NCBI ID: G64151

NCAPG

NCAPG: A Protein Targeted for Cancer Treatment

NCAPG (N-cadherin-associated protein G) is a protein that is expressed in various tissues throughout the body, including the nervous system, and is known for its role in cell-cell adhesion. NCAPG has been identified as a potential drug target and biomarker for various diseases, including cancer.

The NCAPG protein is composed of 150 amino acid residues and has a calculated molecular weight of 19.9 kDa. It is located in the cytoplasm and is associated with the cytoskeleton. NCAPG is a member of the cadherin family of transmembrane proteins, which are involved in cell-cell adhesion and signaling.

NCAPG has been shown to play a role in several physiological processes in the body, including cell division, migration, and invasion. In addition, NCAPG has been linked to several diseases, including cancer.

One of the main functions of NCAPG is its role in cell-cell adhesion. NCAPG is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of tissues. In addition, NCAPG is involved in the regulation of cell migration and invasion.

NCAPG has also been shown to play a role in the regulation of cell proliferation. In addition, NCAPG has been linked to the development and progression of several types of cancer, including breast, ovarian, and prostate cancer.

Due to its involvement in several physiological processes and its potential as a drug target, NCAPG has become a focus of research in recent years. Studies have shown that inhibiting NCAPG may be an effective way to treat several types of cancer.

One of the main strategies for targeting NCAPG is the use of small molecules. Many small molecules have been shown to interact with NCAPG and to have potential as drug candidates. One of the most promising small molecules is a compound called U-8719, which is a inhibitor of NCAPG.

U-8719 has been shown to be effective in cell experiments for several types of cancer, including breast, ovarian, and prostate cancer. In addition, U-8719 has been shown to downregulate the expression of NCAPG, which suggests that it may be an effective way to treat cancer.

Another approach to targeting NCAPG is the use of antibodies. Many antibodies have been shown to interact with NCAPG and to have potential as drug candidates. One of the most promising antibodies is a monoclonal antibody called mTMC-235.

mTMC-235 has been shown to be effective in cell experiments for several types of cancer, including breast, ovarian, and prostate cancer. In addition, mTMC-235 has been shown to inhibit the interaction of NCAPG with its ligand, suggesting that it may be an effective way to treat cancer.

In conclusion, NCAPG is a protein that is involved in several physiological processes and has been linked to several diseases, including cancer. The potential of NCAPG as a drug target and biomarker makes it an attractive target for research in the field of cancer. The use of small molecules and antibodies, such as U-8719 and mTMC-235, have shown promise in targeting NCAPG and may be effective ways to treat cancer. Further research is needed to fully understand the role of NCAPG in cancer and to develop effective treatments.

Protein Name: Non-SMC Condensin I Complex Subunit G

Functions: Regulatory subunit of the condensin complex, a complex required for conversion of interphase chromatin into mitotic-like condense chromosomes. The condensin complex probably introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases and converts nicked DNA into positive knotted forms in the presence of type II topoisomerases

The "NCAPG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NCAPG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets